Endo International – Recall of Robaxin® (methocarbamol)

- On September 28, 2018, Endo Pharmaceuticals announced a voluntary consumer-level recall of two lots of Robaxin (methocarbamol) 750 mg tablets because the products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily."

- The recalled lots were distributed by wholesale distributors to retail pharmacies. No other lots are affected by this recall.

Product Description	NDC #	Lot # (expiration date)
Robaxin (methocarbamol) 750 mg tablets, 100-count bottle pack	52244-449-10	216702P1 (9/2020) 220409P1 (1/2021)

- Robaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

- Patients who follow the directions on the recalled Robaxin bottle may experience significant drowsiness or dizziness which would put them at risk of falls or an overdose which could result in seizures, coma, or death. To date, Endo Pharmaceuticals has not received any reports of adverse events related to this recall.

- Distributors and retailers should stop distribution and dispensing of the recalled Robaxin product and return it to the place of purchase.

- Consumers in possession of any unused prescribed Robaxin 750 mg product bearing lot numbers 216702P1 or 220409P1 should discontinue use of the product and contact Inmar at 1-866-391-0620 for return and reimbursement information.

- Distributors, retailers and consumers with questions regarding this recall can contact Inmar by phone or by email at robaxin@inmar.com.

- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.